Proteolysis by calpains: A possible contribution to degradation of p53

Molecular and Cellular Biology

Volumn 17, Issue 5, 1997, Pages 2806-2815

  Pariat, Magali ^a   Carillo, Serge ^a   Molinari, Marta ^b   Salvat, Catherine ^a   Debüssche, Laurent ^c   Bracco, Laurent ^c   Milner, Jo ^b   Piechaczyk, Marc ^a  

^a CNRS   (France)

^b UNIVERSITY OF YORK   (United Kingdom)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM IONOPHORE; CALPAIN; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; CYTOPLASM; ENZYME SUBSTRATE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; TUMOR CELL;

ANIMALIA; MAMMALIA;

EID: 0030987086     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.5.2806     Document Type: Article

References (75)

1. Bakalkin, G., T. Yakovleva, G. Selivanova, K. P. Magnusson, L. Szekely, E. Kiseleva, G. Klein, L. Terenius, and K. G. Wiman. 1994. P53 binds single-stranded DNA ends and catalyzes DNA denaturation and strand transfer. Proc. Natl. Acad. Sci. USA 91:411-417.
2. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565-2574.
3. Bargonetti, J. P., N. Friedman, S. E. Kern, B. Vogelstein, and C. Prives. 1991. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083-1091.
4. Carillo, S., M. Pariat, I. Jariel-Encontre, A.-M. Steff, F. Poulat, P. Bertha, and M. Piechaczyk. 1996. PEST motifs are not required for rapid calpain-mediated proteolysis of c-FOS protein. Biochem. J. 313:245-251.
5. Carillo, S., M. Pariat, A.-M. Steff M. Etienne-Julan, T. Lorca, and M. Piechaczyk. 1994. Differential stability of FOS and JUN family members to calpains. Oncogene 9:1679-1689.
6. Carillo, S., M. Pariat, A.-M. Steff, P. Roux, M. Etienne-Julan, T. Lorca, and M. Piechaczyk. 1994. Differential sensitivity of FOS and JUN family members to calpains. Oncogene 9:1679-1689.
7. Chin, K. V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459-462.
8. Chiu, R., W. Boyle, J. Meek, T. Smeal, T. Hunter, and M. Karin. 1988. The c-fos protein interacts with c-jun/AP-1 to stimulate transcription of AP-1 responsive genes. Cell 54:541-552.
9. Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14:1997-2003.
10. Ciechanover, A., D. Shkedy, M. Oren, and B. Bercovich. 1994. Degradation of the tumor suppressor protein p53 by the ubiquitin-mediated proteolytic system requires a novel species of ubiquitin-carrier protein, E2. J. Biol. Chem. 269:9582-9589.
11. Croall, D. E., and G. N. DeMartino. 1991. Calcium-activated neutral protease (calpain) system: structure, function, and regulation. Physiol. Rev. 71:813-847.
12. Delphin, C., P. Cahen, J. J. Lawrence, and J. Baudier. 1994. Characterization of baculovirus recombinant wild-type p53. Eur. J. Biochem. 223:683-692.
13. Donehower, L. A., and A. Bradley. 1993. The tumor suppressor gene p53. Biochim. Biophys. Acta 1155:181-205.
14. Dulic, V., W. K. Kaufmann, S. J. Wilson, T. D. Tlsty, E. Lees, J. W. Harper, S. J. Elledge, and S. I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023.
15. El-Deiry, W. S., S. E. Kinzler, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49
16. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
17. Farmer, G., J. Bargonetti, H. Zhu, P. Friedman, R. Priwes, and C. Prives. 1992. Wild-type p53 activates transcription in vitro. Nature 358:83-86.
18. Fields, S., and S. K. Jang. 1990. Wild-type p53 activates transcription in vitro. Science 249:1046-1049.
19. Fujiwara, T., D. W. Cai, R. N. Georges, T. Mukhopadhyay, A. A. Grimm, and J. A. Roth. 1994. Therapeutical effect of a retroviral wild-type vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86:1458-1462.
20. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
21. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979-9983.
22. Goldberg, A. L., and K. Rock. 1992. Proteolysis, proteasome and antigen presentation. Nature 357:375-379.
23. Greenblatt, M. S., W. P. Bennett, M. Hollstein, and C. C. Harris. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878.
24. Gronostajski, R. M., A. L. Goldberg, and A. B. Pardee. 1984. Energy requirement for degradation of tumor-associated protein p53. Mol. Cell. Biol. 4:442-448.
25. Hershko, A., and A. Ciechanover. 1992. The ubiquitin system for protein degradation. Annu. Rev. Biochem. 61:761-807.
26. Hirai, S., H. Kawasaki, M. Yaniv, and K. Suzuki. 1991. Degradation of transcription factors, c-Jun and c-Fos, by calpain. FEBS Lett. 287:57-61.
27. Jennissen, H. P. 1995. Ubiquitin and the enigma of intracellular protein degradation. Eur. J. Biochem. 231:1-30.
28. Kastan, M. B., Q. Zhan, W. El-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597.
29. Kern, S. E., K. W. Kinzler, A. Brudskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252:1708-1711.
30. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 249:827-830.
31. Kinzler, K. W., and B. Vogelstein. 1996. Life (and death) in a malignant tumor. Nature 379:19-20.
32. Ko, J. K., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
33. Kubbutat, M. H. G., and K. H. Vousden. 1997. Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17:460-468.
34. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
35. Lane, R. D., D. M. Allan, and R. Mellgren. 1992. A comparison of the intracellular distribution of micro-calpain, milli-calpain and calpastatin in proliferating human A431 cells. Exp. Cell Res. 203:5-16.
36. Legros, Y., V. Lacabanne, M. F. D'agay, C. J. Larsen, M. Pla, and T. Soussi. 1993. Isolation of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull. Fr. Cancer 80:102-110.
37. Leveillard, T., L. Andrea, N. Bissonnette, L. Scheffer, L. Bracco, J. M. Egly, and B. Wasylyk. 1996. Functional alterations between p53 and the TFIIH complex are affected by tumor-associated. EMBO J. 15:1615-1624.
38. Maki, C. G., J. Huibregtse, and P. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 56:2649-2654.
39. Maki, M., H. Bagci, K. Hamaguchi, M. Ueda, T. Murachi, and M. Hatanaka. 1989. Inhibition of calpain by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J. Biol. Chem. 254:18866-18869.
40. Masuda, H., C. Miller, H. P. Koeffler, H. Battifora, and M. T. Cline. 1987. Rearrangement of the p53 gene in human osteogenic sarcoma. Proc. Natl. Acad Sci. USA 84:7716-7719.
41. Medcalf, E. A., T. Takahashi, I. Chiba, J. Minna, and J. Milner. 1992. Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene 7:71-76.
42. Mellgren, R. L. 1991. Proteolysis of nuclear proteins by mu-calpain and m-calpain. J. Biol. Chem. 266:13920-13924.
43. Mellgren, R. L., and Q. Lu. 1994. Selective nuclear transport of microcalpain. Biochem. Biophys. Res. Commun. 204:544-550.
44. Mellgren, R. L., K. Song, and M. T. Mericle. 1993. m-calpain requires DNA for activity on nuclear proteins at low calcium concentrations. J. Biol. Chem. 268:653-657.
45. Michalovitz, D., O. Haley, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-681.
46. Milner, J. 1995. Flexibility: the key to p53 function? Trends Biochem. Sci. 20:49-51.
47. Milner, J. 1994. Forms and functions of p53. Cancer Biol. 5:211-219.
48. Milner, J., Y. S. Chan, E. A. Medcalf, Y. Wand, and W. Eckhardt. 1993. Partially transformed T3T3 cells express high levels of mutant p53 in the "wild-type" immunoreactive form with defective oligomerization. Oncogene 8:2001-2008.
49. Milner, J., and E. A. Medcalf. 1990. Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135. J. Mol. Biol. 216:481-484.
50. Molinari, M., and J. Milner. 1995. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6. Oncogene 10:1849-1854.
51. Mosner, J., T. Mummenbrauer, C. Bauer, G. Sczakiel, F. Grosse, and W. Deppert. 1995. Negative feedback regulation of wild-type p53 biosynthesis. EMBO J. 14:4442-4449.
52. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13:4816-4822.
53. Oren, M. 1992. p53: the ultimate tumor suppressor gene? FASEB J. 6:3169-3176.
54. Oren, M. 1994. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5:221-227.
55. Pavletich, N., K. A. Chambers, and C. O. Pabo. 1993. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot-spots. Genes Dev. 7:2556-2564.
56. Raycrott, L., H. Wu, and G. Lozano. 1990. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049-1051.
57. Rolley, N., S. Butcher, and J. Milner. 1995. Specific DNA binding by different classes of human p53 mutants. Oncogene 11:763-770.
58. Rolley, N., and T. Milner. Unpublished data.
59. Saido, T. C., H. Sorimachi, and K. Suzuki. 1994. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. 8:814-822.
60. Salvat, C., I. Jariel-Encontre, M. Pariat, C. Acquaviva, I. Robbins, and M. Piechaczyk. Regulation of transcription factor activity by proteolysis in eucaryotic cells, in press. Research Signpost, Trivandrum, India.
61. Scheffner, M., J. M. Huibregtse, and P. M. Howley. 1994. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA 91:8797-8801.
62. Scheffner, M., U. Nuber, and J. M. Huibregtse. 1995. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature 373:81-83.
63. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
64. Schweghoffer, F., I. Barlat, M. C. Chevallier-Multon, and B. Tocqué. 1992. Implication of GAP in ras-dependent transactivation of a Polyoma enhancer sequence. Science 256:825-827.
65. Shkedy, D., H. Gonen, B. Bercovich, and A. Ciechanover. 1994. Complete reconstitution of conjugation and subsequent degradation of the tumor suppressor protein p53 by purified components of the ubiquitin proteolytic system. FEBS Lett. 348:126-130.
66. Sturges, M. R., and L. J. Peck. 1994. Calcium-dependent inactivation of RNA polymerase III transcription. J. Biol. Chem. 269:5712-5719.
67. Sturzbecher, H. W., B. Donzelmann, W. Henning, U. Knippschild, and S. Buchhop. 1996. p53 is linked to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15:1992-2002.
68. Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757-4762.
69. Ueba, T., T. Nosaka, J. A. Takahashi, F. Shibata, R. Z. Florkiewicz, B. Vogelstein, Y. Oda, H. Kikuchi, and M. Hatanaka. 1994. Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sei. USA 91: 9009-9013.
70. Unger, T., M. M. Nau, S. Segal, and J. D. Minna. 1992. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11:1383-1390.
71. Wang, K. K. W. 1990. Developing selective inhibitors of calpains. Trends Biochem. Sci. 11:139-142.
72. Watt, F., and P. L. Molloy. 1993. Specific cleavage of transcription factors by the thiol protease, m-calpain. Nucleic Acids Res. 21:5092-5100.
73. Yamato, K., M. Yamamoto, Y. Hirano, and N. Tsuchida. 1995. A human temperature sensitive mutant p53-Val138: modulation of the cell cycle, viability and expression of p53-responsive genes. Oncogene 11:1-6.
74. Zambetti, G. P., and A. J. Levine. 1993. A comparison of the wild-type and mutant p53. FASEB J. 7:855-865.
75. Zerrahn, J., W. Deppert, D. Weidemann, T. Patschinsky, F. Richards, and J. Milner. 1992. Correlation between the conformational phenotype of p53 and its subcellular location. Oncogene 7:1371-1381.